Dogwood Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Dogwood Therapeutics, Inc. (DWTX) reported Increase (Decrease) in Accounts Payable of -$325.86 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- Dogwood Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $263.65K.
- Dogwood Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$589.51K.
- Dogwood Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $118.97K.
- Dogwood Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $86.73K, a 71.79% decline year-over-year.
- Dogwood Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$532.61K, a 342.22% decline from fiscal 2024.
- Dogwood Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $219.89K.
- Dogwood Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$461.25K, a 310.33% decline from fiscal 2022.
- Dogwood Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $219.30K, a 18.78% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $263.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$325.86K 10-Q · filed 2026-08-14 | -$206.90K derived: sum of 3 quarters · filed 2026-08-14 | -$120.16K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$589.51K 10-Q · filed 2026-05-15 | -$470.55K derived: sum of 2 quarters · filed 2026-05-15 | -$383.81K derived: sum of 3 quarters · filed 2026-05-15 | -$990.64K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $118.97K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $205.70K derived: sum of 2 quarters · filed 2026-03-18 | -$401.13K derived: sum of 3 quarters · filed 2026-08-14 | -$532.61K 10-K · filed 2026-03-18 |
| 2025-09-30 | $86.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$520.10K derived: sum of 2 quarters · filed 2026-08-14 | -$651.57K 10-Q · filed 2025-11-07 | -$774.73K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$606.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$738.31K 10-Q · filed 2026-08-14 | -$861.47K derived: sum of 3 quarters · filed 2026-08-14 | -$554.04K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$131.48K 10-Q · filed 2026-05-15 | -$254.64K derived: sum of 2 quarters · filed 2026-05-15 | $52.79K derived: sum of 3 quarters · filed 2026-05-15 | $3.56K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$123.16K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $184.27K derived: sum of 2 quarters · filed 2026-03-18 | $135.04K derived: sum of 3 quarters · filed 2026-03-18 | $219.89K 10-K · filed 2026-03-18 |
| 2024-09-30 | $307.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $258.20K derived: sum of 2 quarters · filed 2025-11-07 | $343.05K 10-Q · filed 2025-11-07 | $249.59K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$49.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $35.62K 10-Q · filed 2025-08-13 | -$57.83K derived: sum of 3 quarters · filed 2025-08-13 | -$66.77K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $84.85K 10-Q · filed 2025-05-09 | -$8.61K derived: sum of 2 quarters · filed 2025-05-09 | -$17.55K derived: sum of 3 quarters · filed 2025-05-09 | $61.66K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$93.46K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$102.39K derived: sum of 2 quarters · filed 2025-03-31 | -$23.18K derived: sum of 3 quarters · filed 2025-03-31 | -$461.25K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$8.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $70.28K derived: sum of 2 quarters · filed 2024-11-08 | -$367.80K 10-Q · filed 2024-11-08 | -$440.37K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $79.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$358.86K 10-Q · filed 2024-08-09 | -$431.43K derived: sum of 3 quarters · filed 2024-08-09 | -$451.23K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$438.07K 10-Q · filed 2024-05-10 | -$510.64K derived: sum of 2 quarters · filed 2024-05-10 | -$530.44K derived: sum of 3 quarters · filed 2024-05-10 | -$195.60K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$72.57K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | -$92.37K derived: sum of 2 quarters · filed 2024-03-08 | $242.47K derived: sum of 3 quarters · filed 2024-03-08 | $219.30K 10-K/A · filed 2024-03-08 |
| 2022-09-30 | -$19.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $315.05K derived: sum of 2 quarters · filed 2023-11-13 | $291.87K 10-Q · filed 2023-11-13 | $162.24K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $334.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $311.68K 10-Q · filed 2023-08-11 | $182.04K derived: sum of 3 quarters · filed 2023-08-11 | $402.95K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$23.17K 10-Q · filed 2023-05-12 | -$152.81K derived: sum of 2 quarters · filed 2023-05-12 | $68.10K derived: sum of 3 quarters · filed 2023-05-12 | -$283.97K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$129.63K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $91.27K derived: sum of 2 quarters · filed 2023-03-14 | -$260.80K derived: sum of 3 quarters · filed 2023-03-14 | $270.01K 10-K · filed 2023-03-14 |
| 2021-09-30 | $220.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$131.16K derived: sum of 2 quarters · filed 2022-11-14 | $399.64K 10-Q · filed 2022-11-14 | $295.06K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$352.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $178.73K 10-Q · filed 2022-08-12 | $74.16K derived: sum of 3 quarters · filed 2022-08-12 | $94.99K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $530.80K 10-Q · filed 2022-05-13 | $426.22K derived: sum of 2 quarters · filed 2022-05-13 | $447.06K derived: sum of 3 quarters · filed 2022-05-13 | $508.51K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$104.58K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$83.74K derived: sum of 2 quarters · filed 2022-03-18 | -$22.29K derived: sum of 3 quarters · filed 2022-03-18 | $51.56K 10-K · filed 2022-03-18 |
| 2020-09-30 | $20.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $82.29K derived: sum of 2 quarters · filed 2021-11-12 | $156.14K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $61.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $135.30K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $73.85K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |